ROCKVILLE, Md., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company overview and host investor meetings at the following investor conferences:
|
Stifel Healthcare Conference |
|
Presentation Date: Tuesday, November 18 |
|
Time: 10:55 A.M. |
|
Place: New York Palace Hotel, New York City |
|
|
|
Piper Jaffray Healthcare Conference |
|
Presentation Date: Wednesday, December 3 |
|
Time: 2:30 P.M. |
|
Place: New York Palace Hotel, New York City |
Investors interested in arranging a meeting during this conference should contact the respective conference coordinators.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
INVESTOR CONTACT:
COCKRELL GROUP
877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Source:
Supernus Pharmaceuticals, Inc.
News Provided by Acquire Media